| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10008947 | Annals of Allergy, Asthma & Immunology | 2005 | 7 Pages |
Abstract
Desloratadine-pseudoephedrine, 5/240-mg once-daily tablets, provided additional benefit over desloratadine, 5 mg, or sustained-release pseudoephedrine, 240 mg, monotherapy in the treatment of patients with SAR and moderate-to-severe nasal congestion.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Warren MD, Robert MD, Steven MD, Barry PhD,